Applications and advances of multi-omics technologies in gastrointestinal tumors
Yuqing Liu, Feng Gao, Yang Cheng and 2 more
Frontiers in Medicine · 2025
doi:10.3389/fmed.2025.1630788 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Gastrointestinal tumors pose a significant clinical challenge due to their high heterogeneity and the difficulties in early diagnosis. The article systematically reviews the latest advances in multi-omics technologies in gastrointestinal tumor research, focusing on their contributions to early screening, biomarker discovery, and treatment optimization. Genomics reveals genetic characteristics and heterogeneity of tumors; transcriptomics helps identify molecular subtypes and potential therapeutic targets; proteomics provides important information on core proteins and the immune microenvironment; and metabolomics offers promising biomarkers for early diagnosis. Furthermore, emerging fields such as epigenomics, metagenomics, and lipidomics, through the construction of multi-scale frameworks, have opened new paths for molecular subtyping and targeted therapy. By integrating these multi-dimensional data, multi-omics integration enables a panoramic dissection of driver mutations, dynamic signaling pathways, and metabolic-immune interactions. However, challenges such as data heterogeneity, insufficient algorithm generalization, and high costs limit clinical translation. In the future, the integration of single-cell multi-omics, artificial intelligence, and deep learning technologies with multi-omics may offer more efficient strategies for the precise diagnosis and personalized treatment of gastrointestinal tumors.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.